What is the CVR number of PHARMA EVIDENCE ApS?

PHARMA EVIDENCE ApS is registered with CVR / Virk under CVR 34586519.

What is the revenue of PHARMA EVIDENCE ApS?

PHARMA EVIDENCE ApS reported revenue of DKK -158K in 2024.

How many employees does PHARMA EVIDENCE ApS have?

PHARMA EVIDENCE ApS employs 1 people as of the latest annual report.

Who is the CEO of PHARMA EVIDENCE ApS?

Tove Holm-Larsen is Management of PHARMA EVIDENCE ApS, in role since 2012.

Where is PHARMA EVIDENCE ApS headquartered?

PHARMA EVIDENCE ApS's registered address is Sommervej 9.

PHARMA EVIDENCE ApS

APSActive

CVR 34586519Sommervej 9Research and experimental development on natural sciences and engineering · NACE 7210Est. 20121 employees

Full Risika report

Revenue 2024

DKK -158K

-63% vs 2023

EBITDA margin

117.3%

+77% vs 2023

Equity ratio

34.1%

Financial strength

Net profit 2024

DKK -180K

+77% vs 2023

EBITDA — year on yearDKK millions

Key figuresAnnual report 2024

Revenue	DKK -158K	-63%
EBITDA	DKK -185K	+77%
Net profit	DKK -180K	+77%
Total assets	DKK 212K	-73%
Equity	DKK 72K	-71%
Employees	1	—

Item	2020	2021	2022	2023	2024
Revenue	1.073	196	552	-428	-158
Staff expenses	-238	-644	-412	-381	-27
EBITDA	834	-448	140	-810	-185
Depreciation & amort.	-0	-0	-0	-0	-0
EBIT	834	-448	140	-810	-185
Net financials	-6	6	-5	10	5
Profit before tax	828	-442	135	-799	-180
Tax	185	-0	-63	-3	-0
Net profit	643	-442	197	-796	-180

Item	2020	2021	2022	2023	2024
Total assets	1.850	1.320	1.268	784	212
Equity	1.293	851	1.048	252	72
Long-term debt	0	0	0	0	0
Short-term debt	557	469	220	532	140
Total debt	557	469	220	532	140

Name	Role	Member since
Current (1)
TH Tove Holm-Larsen Management	Management	2012

Shareholder	Type	Ownership	Votes	Since
HB World Holding ApS	Company	100%	100%	2018

Person	Role here	Other companies
Tove Holm-Larsen	Management	0 companies

PHARMA EVIDENCE ApS

APSActive

CVR 34586519Sommervej 9Research and experimental development on natural sciences and engineering · NACE 7210Est. 20121 employees

Full Risika report

Revenue 2024

DKK -158K

-63% vs 2023

EBITDA margin

117.3%

+77% vs 2023

Equity ratio

34.1%

Financial strength

Net profit 2024

DKK -180K

+77% vs 2023

EBITDA — year on yearDKK millions

Key figuresAnnual report 2024

Revenue	DKK -158K	-63%
EBITDA	DKK -185K	+77%
Net profit	DKK -180K	+77%
Total assets	DKK 212K	-73%
Equity	DKK 72K	-71%
Employees	1	—